Transaction · 0000905148-26-003836

Blume-Jensen Peter

Blume-Jensen Peter, PRES, reported an open-market or private sale at Acrivon Therapeutics, Inc. involving 484.000000 shares for an estimated $972.84. Reported holdings after the transaction were 385859.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SPRES
ACRVAcrivon Therapeutics, Inc.
Filing timeAug 20
Trade dateAug 18, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$2.20
Pre-filing
1mo ago -20.5%1w ago -21.4%1d ago -7.3%
Returns since
7d -2.3%30d -6.4%90d -6.4%180d -6.4%1y -6.4%

ACRV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ACRV since 2026-08-20Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000905148-26-003836
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 08:07 PM · 2d delay
Shares
484 sh
$201 per share
Estimated value
-$97.2k
Computed from shares × price
Holdings after
385k sh
Indirect · See Footnote
+4score
Filing-only score

+4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

  2. F2

    These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of h…

  3. F3

    These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of…

Original filing · 0000905148-26-003836
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ACRV